New Protein Target Could Enhance Leukemia Treatment
Researchers identified a protein that helps leukemia cells survive, potentially offering a way to improve current therapies.
Updated on Oct. 25, 2026 in Cancer
Researchers have identified a protein called NYNRIN that acts as a survival mechanism for leukemia stem cells in acute myeloid leukemia. Targeting this protein may help increase the efficacy of existing treatments like venetoclax by making the cancer cells more vulnerable to cell death.
Why it matters
NYNRIN allows leukemia stem cells to thrive by managing toxic cellular stress, which is linked to a poorer prognosis for patients. Understanding this pathway offers a new target for future research into therapies that can better overcome cancer cell resistance.
This preclinical study identified NYNRIN as a protein highly expressed in leukemia stem cells and correlated with poor prognosis. The findings suggest that targeting this pathway could lower the apoptotic threshold of cancer cells, though clinical applications remain under investigation.
The details
NYNRIN functions by binding to and degrading the mRNA of a protein called TXNIP. When NYNRIN is inhibited, TXNIP accumulates and disrupts the cell's ability to buffer reactive oxygen species, which leads to programmed cell death. By suppressing this specific RNA-binding protein, researchers were able to increase the effectiveness of the drug venetoclax against the stem cells.
Timeline
- 2026-10-25
Research findings regarding the role of NYNRIN in leukemia were published.
Health Landscape
This research sits within the ongoing effort to overcome treatment resistance in acute myeloid leukemia by targeting the survival pathways of stem cells. It contributes to a broader shift in oncology toward identifying specific molecular vulnerabilities that enhance the success of established drugs.
This molecular discovery is currently in the laboratory research phase and does not change clinical care or treatment decisions for patients today. Those currently undergoing leukemia treatment should continue to follow their physician's guidance regarding established protocols.
The takeaway
Targeting specific proteins like NYNRIN could eventually improve leukemia treatment outcomes by disrupting cancer cell survival. Patients should continue to discuss their specific treatment plan and any clinical trial eligibility with their oncology team.
Further reading
For more on new research and treatment approaches, visit Cancer.
More information
Read the original Nature research article for full study details.
Source note: This article includes information reported by Nature.
